MedPath

Taurine Eye Drops May Prevent the Progression of Cataract

Phase 1
Active, not recruiting
Conditions
Cataract
Interventions
Registration Number
NCT06639711
Lead Sponsor
University Of Anbar
Brief Summary

The aim of the current intervention study is to determine the effectiveness of taurine containing eye drops (available under brand name VIZILOTON) to prevent the progression of grade I and II senile cataract.

This study could answer:

* Dose continuous use of taurine-containing eye drops could prevent further deterioration of vision in mild cases of cataract?

* The acceptance/ compliance of participants to taurine-containing eye drops.

* Could long-term use of taurine-containing eye drops cause adverse effect(s)?

Participants will:

* Take taurine-containing eye drops (VIZILOTON eye drops) 4 times a day for one year.

* Visit eye clinic every 3 months for assessment and visual examination.

* Keep notes for their symptoms and their adherence to treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria
  • The presence of grade I or II senile cataract on one or two eyes.
Exclusion Criteria
  • clinical signs of glaucoma
  • history of amblyopia, eye surgery, argon or YAG laser eye treatment, or major eye trauma
  • history of iritis, retinal crystalline deposits, or optic nerve disease
  • visually significant fundus pathology

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Application of Taurine-containing Eye DropsTaurine-
Primary Outcome Measures
NameTimeMethod
Visual Acuity1 Year
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Al-Nahrain Eye Clinics

🇮🇶

Ramadi, Anbar, Iraq

© Copyright 2025. All Rights Reserved by MedPath